TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe nonproliferative diabetic retinopathy (NPDR) \[(diabetic retinopathy severity scale (DRSS) levels 47 or 53)\], confirmed by the central reading center, in whom panretinal photocoagulation (PRP) can be safely deferred for at least 6 months per the investigator~2. Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)~Key Exclusion Criteria:~1. Presence of diabetic macular edema (DME) threatening the center of the macula in the study eye~2. Evidence of retinal neovascularization on clinical examination or Fluorescein Angiography (FA)~3. Any prior focal or grid laser photocoagulation or any prior PRP in the study eye~4. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or intravitreal (IVT) anti-VEGF treatment in the study eye~5. Any prior intraocular steroid injection in the study eye~6. Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional retinal detachment visible at the screening assessments in the study eye~Note: Other inclusion/ exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing regimen 1 (Type: EXPERIMENTAL): Participants will receive IVT aflibercept dosing regimen 1
- Dosing regimen 2 (Type: EXPERIMENTAL): Participants will receive IVT aflibercept dosing regimen 2
- Dosing regimen 3 (Type: SHAM_COMPARATOR): Participants will receive matching sham injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
The following are general criteria; more specific criteria are included in the study protocol:~Inclusion Criteria:~* NYHA Class IIIB/IV (refer to Appendix IV for definitions)~* Left ventricular ejection fraction (LVEF) ≤ 25%~* Not currently listed for heart transplantation, and not planned in next 12 months~* On optimal medical management~* Limited functional status as demonstrated by 6MWT \<300 meters~* At least:~  * One hospitalization for HF in last 12 months or~ * At least 2 unscheduled emergency room or infusion clinic visits (may include intravenous diuretic therapy, etc.) for HF in last 12 months~Exclusion Criteria:~* Presence of mechanical aortic or mitral valve, including planned conversion to bioprosthesis~* Platelet count \< 100,000/mi within 48 prior to enrollment~* Any inotrope use within 30 days prior to enrollment~* Inability to perform 6MWT for any reason~* Any condition, other than heart failure, that could limit survival to less than 2 years~* History of cardiac or other organ transplant~* Existence of any ongoing mechanical circulatory support (including intraaortic balloon pump, temporary circulatory support devices, etc.) at the time of enrollment~* Presence of active, uncontrolled, systemic infection~* History of an unresolved stroke within 90 days prior to enrollment, or a history of cerebral vascular disease with significant (\> 80%)extracranial stenosis~* Contraindication to anticoagulation/antiplatelet therapy~* CRT or CRT-D within 3 months prior to enrollment~* Coronary revascularization (e.g. CABG, PCI) within 3 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- HM II (HeartMate II LVAD) (Type: None): Subjects who elect to, and receive HM II LVAD therapy at baseline
- OMM (Optimal Medical Management) (Type: None): Subjects who elect to remain on optimal medical management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib as a Post-tonsillectomy Pain Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years~* Indication for tonsillectomy (patients undergoing a tonsillectomy as a portion of additional surgical procedures will not be included)~* Have the ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* History of bleeding disorders~* History of liver or kidney dysfunction~* History of allergy to sulfa containing medications~* History of lactose intolerance~* History of asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs~* Women who are currently pregnant, nursing, or trying to conceive~* History of allergy or intolerance to acetaminophen or hydrocodone~* History of allergy to any COX-2 inhibitor, including celecoxib or rofecoxib.~* PT, PTT, hemoglobin, or hematocrit values that are outside of institutional limits.~* History of cardiovascular disease~* Patients currently taking celecoxib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Celecoxib 200 mg tablets
- B (Type: PLACEBO_COMPARATOR): Placebo with same dosing schedule as the active comparator arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OCS Liver PROTECT Trial: Preserving and Assessing Donor Livers for Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Registered male or female primary Liver transplant candidate~* Age ≥18 years old~* Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information~Exclusion Criteria:~* Acute, fulminant liver failure~* Prior solid organ or bone marrow transplant~* Chronic use of hemodialysis or diagnosis of chronic renal failure, defined as chronic serum creatinine of \>3 mg/dl for \>2 weeks and/or requiring hemodialysis~* Multi-organ transplant~* Ventilator dependent~* Dependent on \> 1 IV inotrope to maintain hemodynamics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCS Liver System (Type: EXPERIMENTAL): OCS Liver System
- Control (Type: OTHER): Standard of care (ice)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese Infants, 6 Weeks Through 12 Weeks Of Age~Exclusion Criteria:~* History Of Known Prior Rotavirus Gastroenteritis~* Subjects Who Are Concurrently Participating In Or Are Anticipated To Participate In Other Studies Of Investigational Products At Any Time During The Study Period

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq™
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* presenting to Maricopa Medical Center ED with cutaneous abscess requiring incision and drainage~Exclusion Criteria:~* known sensitivity to Aquacel~* pregnant, nursing, or expecting to become pregnant~* incarcerated patient~* prior treatment of same abscess with incision and drainage~* multiple abscesses~* immunodeficiency~* facial abscess~* suspected osteomyelitis or septic arthritis~* diabetic foot, decubitis, or ischaemic ulcers~* unable to provide informed consent or assent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Iodoform dressing (Type: ACTIVE_COMPARATOR): Iodoform dressing for cutaneous abscess
- Aquacel dressing (Type: ACTIVE_COMPARATOR): Aquacel dressing for cutaneous abscess

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with essential hypertension~Exclusion Criteria:~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of myocardial infarction.~* Other protocol-defined inclusion exclusion criteria also apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Female patients with histologically-confirmed, unresectable locally advanced or metastatic breast cancer;~* Patients should have had either progression during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease or progression during or after (ado-)trastuzumab emtansine treatment for locally advanced or metastatic disease;~* HER2-positive tumor status;~* Patients must have measurable or non-measurable disease that is evaluable per RECIST 1.1;~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;~* Estimated life expectancy \> 12 weeks at randomization;~* Adequate organ function and blood cell counts.~Main Exclusion Criteria:~* Current or previous use of a prohibited medication as listed in the protocol;~* History of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine;~* History of keratitis;~* Severe, uncontrolled systemic disease at screening;~* Left Ventricular Ejection Fraction (LVEF) \< 50%, or a history of clinically significant decrease in LVEF during previous treatment with trastuzumab or (ado-)trastuzumab emtansine;~* Cardiac troponin value above the Upper Limit of Normal (ULN);~* History of clinically significant cardiovascular disease;~* Untreated brain metastases, symptomatic brain metastases, brain metastases requiring steroids to manage symptoms, or treatment for brain metastases within 8 weeks prior to randomization;~* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (vic-)trastuzumab duocarmazine (Type: EXPERIMENTAL): SYD985, every 3 weeks (Q3W)
- Physician's choice (Type: ACTIVE_COMPARATOR): 1. Lap/Cap~2. T/Cap~3. T/Vino~4. T/Eri

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* The patient has a diagnosis of Amyotrophic Lateral Sclerosis (according to El Escorial Criteria, WFN, 1998) and the time from diagnosis of ALS is not be longer than 30 months, or the patient has a diagnosis of multiple sclerosis or probable multiple sclerosis (according to McDonald criteria, 2001)~* The patient has a clinical history and clinical relevant symptoms of Pseudobulbar Affect (PBA)~* CNS-LS score at baseline is 13 or greater~Main Exclusion Criteria:~* Patients with myasthenia gravis~* Any personal history of complete heart block, QTc prolongation, or torsades de pointes~* Any family history of congenital QT interval prolongation syndrome~* Patients with known sensitivity to quinidine, dextromethorphan or opiate drugs (codeine, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DM 30 mg/Q 10 mg (Type: EXPERIMENTAL): AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
- DM 20 mg/ Q 10 mg (Type: EXPERIMENTAL): AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of 5% Lidocaine Medicated Plaster on Allodynic Symptoms of Localized Neuropathic Pain After Knee Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged from 18 to 80 years~* Male or female, for women of childbearing potential, a negative pregnancy test~* Patients with PONP following knee surgery~* Patients with neuropathic pain DN4 ≥ 4~* Patients at least 3 months post-surgery~* Patients suffering from at least the allodynic brush-induced mechanical allodynia symptom (DMA) rated as ≥ 5/10 on the numerical scale~* Patient with no localized neuropathic pain symptoms (DN4\<4) on the contralateral knee~* Intact skin besides the scar of surgery (absence of skin disease, skin irritation, inflammation or injury, such as active herpes zoster lesions, atopic dermatitis, wounds) in the area where the medicated plasters will be applied~* Naive from Versatis® treatment~* Treated with stable systemic analgesic and planned to remain stable all over the duration of the study~* Insured by French social security~* Included or agreement to be included in the national register of participants in biomedical research~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
- placebo (Type: PLACEBO_COMPARATOR): This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mild-to-moderate hypertension, untreated or currently taking antihypertensive therapy.~* Treated patients (using antihypertensive treatments within 4 weeks prior to Visit 1) must have an msSBP ≥ 150 mmHg and \< 180 mmHg at the randomization visit (Visit 201) and msSBP ≥140 mmHg \< 180 mmHg at the visit immediately proceeding Visit 201 (Visit 102 or 103).~* Untreated patients (newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to Visit 1) must have an msSBP ≥ 150 mmHg and \< 180 mmHg at both Visit 1 and Visit 201.~* Patients must have an absolute difference of ≤15 mmHg in msSBP between Visit 201 and the immediately preceding visit;~Exclusion Criteria:~* Severe hypertension (msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg).~* History of angioedema, drug-related or otherwise, as reported by the patient.~* History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension.~* Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 200 mg (Type: EXPERIMENTAL): LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
- LCZ696 400 mg (Type: EXPERIMENTAL): LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
- Olmesartan 20 mg (Type: ACTIVE_COMPARATOR): Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women, aged 20-45, with regular menses and no historical or biochemical secondary cause of osteoporosis.~* Documented adult fractures judged to be low-trauma.~* Must be willing to use effective contraception throughout the period of study drug administration.~Inclusion Criteria - vary slightly based on age category:~* Premenopausal women ages 20-35 years must have at least one major osteoporotic fracture (excluding fractures of fingers, toes and face) and low Bone Mineral Density (BMD).~* Premenopausal women above the age of 35 years should have a history of fracture and/or low BMD.~Exclusion Criteria:~* History of any condition that increases the risk of osteosarcoma~* Early follicular phase serum~* Disorders of mineral metabolism~* Suspicion of osteomalacia~* Vitamin D deficiency~* Pregnancy or lactation within past 12 months~* Prolonged amenorrhea (\> 6 months) during reproductive years (except pregnancy or lactation)~* Prior eating disorder~* Malignancy, except cured basal or squamous cell skin carcinoma~* Endocrinopathy: new onset untreated hyperthyroidism, hypothyroidism, Cushing's syndrome, prolactinoma~* Renal insufficiency~* Liver disease~* Intestinal disorders~* History/current glucocorticoids (GCs), anticonvulsants, anticoagulants, methotrexate, depot progesterone, Gonadotrophin-releasing hormone (GnRH) agonists~* Oral glucocorticoid use (subject will not be excluded if used dose equivalent to less than prednisone 5 mg for \<3 months).~* Current anticoagulant use or low molecular weight~* Depo Provera use (subjects will not be excluded if used at age\>20, \>5 years ago)~* Drugs for osteoporosis (raloxifene, bisphosphonates, denosumab, calcitonin, TPTD). Subjects who discontinue these medications will be eligible 3 months after stopping raloxifene or calcitonin, 12 months after stopping alendronate, risedronate, ibandronate, or pamidronate and 18 months after stopping denosumab. Subjects with prior use of zoledronate may be eligible if received only one dose \>4 years ago. Total bisphosphonate exposure must be \< 1 year. Subjects who have taken TPTD in the past will not be eligible unless used for \<3 months, \> 2 years ago.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Forteo) (Type: ACTIVE_COMPARATOR): Daily injection of Teriparatide for treatment of idiopathic osteoporosis
- Placebo saline injection (Type: PLACEBO_COMPARATOR): Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete